dichlororibofuranosylbenzimidazole has been researched along with Colorectal Neoplasms in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, DM | 1 |
| Won, M | 1 |
| Chung, CS | 1 |
| Kim, S | 1 |
| Yim, HJ | 1 |
| Jung, SH | 1 |
| Jeong, S | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Colorectal Neoplasms
| Article | Year |
|---|---|
JNK-mediated transcriptional upregulation of RhoB is critical for apoptosis of HCT-116 colon cancer cells by a novel diarylsulfonylurea derivative.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Dich | 2010 |